Ethics, pharmacy, policy and pediatric cancer experts publish recommendations for managing and preventing drug shortages
A group of prominent healthcare experts including bioethicists, pharmacists, policymakers and cancer specialists have proposed concrete steps for preventing and managing a nightmare scenario that is becoming all too common: shortages of life-saving drugs.
In a consensus statement published in the journal Pediatrics, the experts say they sought to move away from the current strategy of reaction to shortages once they have occurred and focus instead on prevention. Using the example of shortages of chemotherapy drugs used for treating children with cancer—therapies proven to have high survival rates for the most common childhood cancers—the group developed “a comprehensive blueprint for action” they say is critical for managing and preventing future drug shortages.
“Although our recommendations were developed with pediatric oncology in mind, and serve as a blueprint for preventing children with cancer from lacking access to essential life-saving medications, we believe that they apply more broadly across medicine to include pediatrics and adult medicine in general,” says Yoram Unguru, a pediatric hematologist/oncologist at the Herman and Walter Samuelson Children’s Hospital at Sinai and faculty member at the Johns Hopkins Berman Institute of Bioethics. Unguru, a coauthor of the consensus statement, was the principal organizer of meetings that led to its creation, bringing together representatives from the Food and Drug Administration (FDA), leadership of the Children’s Oncology Group and The American Society of Pediatric Hematology/Oncology, patient advocacy groups, legal scholars and clinicians.
Some recommendations would represent new norms for healthcare practice, including the sharing of scarce drugs between healthcare institutions and not giving preferential access to patients participating in research studies.
“This statement is significant both for the consensus found by such a diverse group of experts, and for being the first to take seriously the ethical rationale to prevent shortages in the first place,” says Matthew DeCamp, a Johns Hopkins professor at the Berman Institute of Bioethics and Division of General Internal Medicine, and lead author of the consensus statement.
Included in the statement’s six recommendations is a call to develop policies that give equal priority to patients regardless of whether they are participants in research. The authors acknowledge this “may be controversial,” due to the sentiment that fairness requires giving research participants high-priority access to drugs because of their contribution to medical knowledge and future patients. However, the statement’s authors explain that “concerns over undue inducement, public perception, and the imperative to use drugs for indications for which evidence of benefit exists outweigh arguments for giving priority access to research participants.”
For each recommendation the statement also includes potential barriers to its implementation. A centralized information source of drug supply information, for instance, faces the risk that such information will encourage hoarding of existing supplies, including so-called “gray market” suppliers that sell scarce drugs for inflated prices. The statement calls for new policies for both reporting and avoiding these markets, though acknowledges the temptation of healthcare providers to use them in a shortage, when their patients are in need.
The Latest on: Shortages of life-saving drugs
via Google News
The Latest on: Shortages of life-saving drugs
- Covid shortages: A black swan pecuniary externalityon April 19, 2021 at 10:09 am
An externality is an effect on a third party that is not directly related to a transaction or an economic activity. That effect can be negative or positive. The classic negative example is when a ...
- Coronavirus: Remdesivir is not a life-saving drug, says health ministryon April 19, 2021 at 7:02 am
Remdesivir is being used to treat critical coronavirus patients, even though medical opinion about its effectiveness has been mixed.
- Delhi govt directs drug inspectors to monitor Remdesivir end-to-endon April 19, 2021 at 5:34 am
Faced with soaring Covid-19 cases in the capital, the Delhi government has now decided to directly oversee the entire procurement and distribution of Remdisivir, and other drugs used to treat ...
- "Not Life-Saving Drug": Centre Clarifies On Remdesiviron April 19, 2021 at 5:32 am
Antiviral drug Remdesivir is not a life-saving drug and its "unnecessary or irrational" use on Covid patients is unethical, the centre tweeted on Monday, amid massive demand for the medicine triggered ...
- Remdesivir not a life-saving drug, does not reduce COVID-19 mortality: Govton April 19, 2021 at 5:29 am
Remdesivir is not a life-saving drug and it cannot decrease the mortality rate, the government said on Monday amid mass hysteria for the anti-viral drug across India as many states reported a shortage ...
- Private hospitals run out of life-saving drugs, oxygen; send SOS to governmenton April 18, 2021 at 5:39 pm
In the wake of exponential surge in Covid cases in the State especially in Bengaluru, many private hospitals are not able admit patients due to shortage of oxygen and life saving drug Remedesivir ...
- K'taka private doctors' body complain of shortage of drugs, oxygenon April 17, 2021 at 8:50 pm
In the wake of exponential surge in Covid cases in Karnataka expecially in Bengaluru, many private hospitals are not able admit patients due to shortage of Oxygen and life saving drug Remedesivir.
- Delhi facing oxygen shortage, no life-saving drugs: Arvind Kejriwalon April 17, 2021 at 6:10 am
Stating that the national capital reported as many as 24,000 new Covid cases in the past 24 hours, Delhi Chief Minister Arvind Kejriwal said Saturday that the city hospitals are running out of oxygen ...
- Remdesivir Not Life-Saving Covid Drug: Maharashtra Task Forceon April 14, 2021 at 12:20 pm
Expressing concern over the panic created by the shortage of Remdesivir, an antiviral drug, Maharashtra's COVID-19 task force has said that it was not a life-saving medicine in coronavirus treatment, ...
- COVID-19: Maharashtra task force notes Remdesivir is no life-saving drugon April 14, 2021 at 9:16 am
Maharashtra's COVID-19 task force has claimed that Remdesivir, an anti-viral drug used in coronavirus treatment is not a life-saving medicine, even as states express concern over the shortage of the ...
via Bing News